These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Utilization of systemic therapy for treatment of advanced urothelial carcinoma: Lessons from real world experience. Swami U; Grivas P; Pal SK; Agarwal N Cancer Treat Res Commun; 2021; 27():100325. PubMed ID: 33549986 [TBL] [Abstract][Full Text] [Related]
29. Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum-containing chemotherapy. A Cochrane Rapid Review. Narayan V; Kahlmeyer A; Dahm P; Skoetz N; Risk MC; Bongiorno C; Patel N; Hwang EC; Jung JH; Gartlehner G; Kunath F Cochrane Database Syst Rev; 2018 Jul; 7(7):CD012838. PubMed ID: 30036453 [TBL] [Abstract][Full Text] [Related]
30. The biology and rationale of targeting nectin-4 in urothelial carcinoma. Heath EI; Rosenberg JE Nat Rev Urol; 2021 Feb; 18(2):93-103. PubMed ID: 33239713 [TBL] [Abstract][Full Text] [Related]
31. The Future of Front-line Metastatic Bladder Cancer is Platinum-free. Young M Eur Urol Focus; 2024 Mar; 10(2):215-216. PubMed ID: 38658299 [TBL] [Abstract][Full Text] [Related]
32. A Podcast on Platinum Eligibility and Treatment Sequencing in Platinum-Eligible Patients with Locally Advanced or Metastatic Urothelial Carcinoma. Gupta S; Moon HH; Sridhar SS Target Oncol; 2024 Jul; 19(4):483-494. PubMed ID: 38963655 [TBL] [Abstract][Full Text] [Related]
33. Optimal Number of Cycles of First-line Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma. Minato A; Ohno D; Murooka K; Okumura Y; Takaba T; Higashijima K; Nagata Y; Tomisaki I; Harada K; Fujimoto N In Vivo; 2024; 38(4):1927-1934. PubMed ID: 38936900 [TBL] [Abstract][Full Text] [Related]
34. [First line therapy for locally advanced or metastatic urothelial cancer : A randomized double blind phase III multicenter study on adjuvant nivolumab therapy versus placebo in patients with invasive high-risk urothelial cancer (CheckMate 274)-AB 58/17 of the AUO]. Rexer H; Ohlmann CH; Gschwend J; Urologe A; 2017 Oct; 56(10):1331-1332. PubMed ID: 28779222 [No Abstract] [Full Text] [Related]
35. The pretreatment neutrophil-to-lymphocyte ratio is a novel biomarker for predicting clinical responses to pembrolizumab in platinum-resistant metastatic urothelial carcinoma patients. Ogihara K; Kikuchi E; Shigeta K; Okabe T; Hattori S; Yamashita R; Yoshimine S; Shirotake S; Nakazawa R; Matsumoto K; Mizuno R; Hara S; Oyama M; Masuda T; Niwakawa M; Oya M Urol Oncol; 2020 Jun; 38(6):602.e1-602.e10. PubMed ID: 32139290 [TBL] [Abstract][Full Text] [Related]
36. Emerging Role of Immunotherapy in Advanced Urothelial Carcinoma. Koshkin VS; Grivas P Curr Oncol Rep; 2018 Apr; 20(6):48. PubMed ID: 29644490 [TBL] [Abstract][Full Text] [Related]
37. Systemic chemotherapy of transitional cell carcinoma of the urothelium. Brinkley WM; Torti FM Semin Surg Oncol; 1997; 13(5):365-75. PubMed ID: 9259093 [TBL] [Abstract][Full Text] [Related]
38. Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial. Nishiyama H; Yamamoto Y; Sassa N; Nishimura K; Fujimoto K; Fukasawa S; Yokoyama M; Enokida H; Takahashi K; Tanaka Y; Imai K; Shimamoto T; Perini R; Frenkl T; Bajorin D; Bellmunt J Int J Clin Oncol; 2020 Jan; 25(1):165-174. PubMed ID: 31729625 [TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of Pembrolizumab versus Carboplatin-based Chemotherapy as First-line Treatment of PD-L1-positive Locally Advanced or Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Therapy in the United States. Hale O; Patterson K; Lai Y; Meng Y; Li H; Godwin JL; Homet Moreno B; Mamtani R Clin Genitourin Cancer; 2021 Feb; 19(1):e17-e30. PubMed ID: 32826180 [TBL] [Abstract][Full Text] [Related]
40. Systemic treatment of advanced and metastatic urothelial cancer: The landscape in Australia. Gurney H; Clay TD; Oliveira N; Wong S; Tran B; Harris C Asia Pac J Clin Oncol; 2023 Dec; 19(6):585-595. PubMed ID: 37727139 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]